Capricor Faces Investor Lawsuits
Capricor Therapeutics faces securities class actions following an FDA regulatory setback and stock plunge.
Anonymous
Key Points
1
The FDA specifically criticized Capricor’s conversion of raw changes into percentage changes and then back into raw changes, saying the approach was not scientifically justified because it added complexity and reduced accuracy.
2
Cantor Fitzgerald analyst Kristen Kluska said the FDA briefing documents “paint an ugly picture” and raised concerns about the integrity of the data collection.
3
The complaints allege that the statistical-plan changes created a significant risk that the FDA would determine Deramiocel’s clinical results did not constitute substantial evidence of effectiveness, putting regulatory approval for Duchenne muscular dystrophy at substantial risk.
4
The complaints further allege that Capricor’s positive statements about its business, operations and prospects were materially misleading or lacked a reasonable basis because of the undisclosed statistical-plan and regulatory risks.
5
Analyst opinion after the regulatory setback was sharply divided: B. Riley raised its rating from neutral to buy and increased its price target from $5 to $21, while Weiss Ratings maintained a sell rating; other upgrades included Piper Sandler to overweight and Oppenheimer to outperform.
Capricor Therapeutics faces multiple securities class actions after the FDA criticized its statistical methods for the Deramiocel heart therapy in July 2026. Rosen Law Firm and other investor rights firms are urging shareholders with losses exceeding $100,000 to file claims by September 28, 2026. The company's stock plummeted 62-64% on July 27 after FDA briefing documents questioned the therapy's effectiveness and benefit-risk profile.
The lawsuits allege Capricor failed to disclose changes to its statistical analysis plan for Deramiocel without FDA approval. ClaimsFiler notes that an FDA advisory committee later voted 9-3 that available evidence did not support the therapy's effectiveness for Duchenne muscular dystrophy. Investor opinions have split sharply since the setback, with some analysts upgrading the stock while others maintain sell ratings.
FDA Criticized Capricor's Statistical Conversion Methods
The FDA flagged a specific statistical problem in Capricor's data analysis. According to FDA briefing documents released July 27, the company converted raw data into percentages, then converted those percentages back into raw numbers. The agency said this approach "was not scientifically justified because it added complexity and reduced accuracy." Cantor Fitzgerald analyst Kristen Kluska said the FDA documents "paint an ugly picture" of the data collection process.
Lawsuits Allege Undisclosed Regulatory Risks
The class action complaints claim Capricor knew about statistical-plan changes that created "significant risk" the FDA would reject Deramiocel. Investors say the company did not disclose these risks in public statements about its business and prospects. The complaints argue Capricor's positive statements were "materially misleading" because they lacked a reasonable basis given the hidden regulatory dangers and flawed statistical methods.
ClaimsFiler reminds investors with losses exceeding $100,000 that they must file lead plaintiff applications by September 28, 2026. Multiple law firms including Rosen Law Firm are handling the class actions. Investors who bought shares between December 17, 2025 and July 26, 2026 may be eligible to participate.
Analyst Ratings Diverge Sharply After FDA Setback
Wall Street split on Capricor after the regulatory shock. B. Riley upgraded the stock from neutral to buy and raised its price target from $5 to $21. Piper Sandler upgraded to overweight and Oppenheimer upgraded to outperform. However, Weiss Ratings maintained a sell rating, citing concerns about the company's prospects.
The sharp rating divergence reflects uncertainty about Capricor's ability to recover from the FDA rejection. Some analysts believe the stock's 62-64% one-day drop created a buying opportunity. Others worry the flawed statistical methods and regulatory rejection signal deeper problems with Deramiocel's development and the company's credibility with regulators.
Sentiment
Mostly NegativeNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
69
Reach
86
A
AnonymousAuthor
